Sub-chronic administration of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers: drug initiation effects and the role of serotonin in experimental anxiety.
The effect in healthy volunteers of administration of the selective serotonin reuptake inhibitor escitalopram (10 mg/day for 3 weeks) vs. placebo on drug initiation effects and experimentally-induced anxiety.
University of Western Australia
28 participants
Aug 10, 2008
Interventional
Conditions
Summary
The purpose of this study is to investigate whether the effect of selective serotonin reuptake inhibitors seen when used to treat anxiety are related to the drug, or to the fact that the people have an anxiety disorder. We expect that we will see "jitteriness" when healthy volunteers start taking the medication, and that the medication will reduce anxiety brought on by an experimental challenge in people who do not have an anxiety disorder.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
escitalopram (10 mg/day for 3 weeks, oral) tryptophan depletion
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000011280